Regeneron Pharmaceuticals Inc.

ticker: REGN step: 01 generated: 2026-05-12 source: quick-research

Regeneron Pharmaceuticals Inc. (REGN) — Business Overview

Business Description

Regeneron is a US biotech company founded by scientist-CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos. The company built its commercial franchise around proprietary recombinant protein and antibody science (notably the VelocImmune mouse platform), generating two of the largest biologic drugs in the world — EYLEA / EYLEA HD (anti-VEGF for retinal disease) and Dupixent (IL-4/IL-13 inhibitor for Type 2 inflammation, partnered with Sanofi). Regeneron is among a small handful of biotech companies that have organically grown to mega-cap scale entirely through internal R&D.

Revenue Model

• Net product sales (Regeneron-recorded): EYLEA / EYLEA HD (US sales recorded by Regeneron; international rights with Bayer), Libtayo (oncology PD-1), Praluent (cardiometabolic), Evkeeza, Veopoz, Inmazeb, Arcalyst.
• Collaboration revenue from Sanofi (Dupixent, Kevzara): Regeneron earns its share of profits from the Sanofi-marketed Dupixent and Kevzara franchises. Dupixent global net sales were $17.8B in 2025 (Sanofi-recorded), with Regeneron earning ~50% of profits.
• Collaboration revenue from Bayer (international EYLEA): Bayer markets EYLEA outside the US and pays Regeneron a profit share.
• Manufacturing & royalty: Smaller line — manufacturing of partner products, royalties on licensed technology.

The earnings model is heavily weighted toward profit share (Dupixent + Bayer EYLEA) — Regeneron's reported revenue understates the true economic exposure to Dupixent.

Products & Services

Anti-VEGF / ophthalmology:

• EYLEA HD (aflibercept 8mg) — high-dose, longer-interval formulation; now >50% of US Eylea volume. Approved for wet AMD, DME, diabetic retinopathy, and macular edema following retinal vein occlusion.
• EYLEA (aflibercept 2mg) — legacy formulation, facing biosimilar competition

Type 2 inflammation:

• Dupixent (dupilumab, with Sanofi) — atopic dermatitis, asthma, EoE, prurigo nodularis, COPD, CSU; >1M patients globally; $17.8B 2025 global sales
• Kevzara (sarilumab, with Sanofi) — rheumatoid arthritis, polymyalgia rheumatica

Oncology:

• Libtayo (cemiplimab) — PD-1 inhibitor for non-melanoma skin cancers, NSCLC, cervical cancer; $1.22B 2024 net sales (+40% YoY)
• Odronextamab — CD20xCD3 bispecific for follicular lymphoma (regulatory submission)
• Linvoseltamab — BCMAxCD3 bispecific for multiple myeloma

Rare diseases:

• Evkeeza (evinacumab) — homozygous familial hypercholesterolemia
• Praluent (alirocumab, with Sanofi outside US) — PCSK9 inhibitor for hypercholesterolemia
• Veopoz (pozelimab) — CHAPLE disease
• Arcalyst (rilonacept) — recurrent pericarditis, CAPS, DIRA
• Inmazeb (atoltivimab/maftivimab/odesivimab) — Ebola

Pipeline: 40+ programs in clinical development across oncology (multiple bispecifics), genetic medicines (gene editing via Intellia partnership), and inflammation/immunology.

Customer Base & Go-to-Market

• US ophthalmologists & retinal specialists: Direct sales for EYLEA HD / EYLEA — buy-and-bill physician administration channel.
• Dermatologists, pulmonologists, allergists, gastroenterologists: Co-promotion with Sanofi for Dupixent across multiple specialties.
• Oncology specialists: Libtayo + emerging bispecific pipeline.
• Payers / public health: US Medicare Part B (EYLEA is a major Part B drug), commercial insurance, Medicaid, international government payers via Sanofi/Bayer subsidiaries.
• Geographic mix (Regeneron-recorded revenue): US-dominant; international exposure is via the Sanofi (Dupixent) and Bayer (EYLEA) profit shares.

No single customer represents material concentration. Sanofi profit-share is the largest single revenue line by economic exposure.

Competitive Position

Regeneron operates at the front of two major biopharma franchises:

• In anti-VEGF retinal disease, EYLEA HD has converted >50% of the US franchise volume in 2025/2026 — a strategic pivot to longer-interval dosing aimed at neutralizing Roche's Vabysmo (faricimab) and the multiple EYLEA biosimilars now in the US market. Recent multiple FDA approvals (RVO indication, pre-filled syringe) have re-stabilized the franchise.
• In Type 2 inflammation, Dupixent has crossed $17.8B global sales (with Sanofi) and continues to expand into new indications. The IL-4Rα franchise is one of the best-positioned biologic platforms in big pharma.

Key competitive advantages: (1) VelocImmune antibody discovery platform — internally generates antibody candidates at scale, (2) deep clinical/commercial integration with Sanofi on Dupixent, (3) Eylea HD high-dose moat vs. biosimilars and Vabysmo, (4) growing oncology bispecific platform (Libtayo + odronextamab + linvoseltamab), (5) founder-led research culture (Yancopoulos, Schleifer) with industry-respected science. Key challenges: EYLEA biosimilar erosion (Amgen, Samsung Bioepis, Biocon, others), competitive intensity from Roche Vabysmo in anti-VEGF, dependency on Dupixent for long-duration growth, and a relatively concentrated commercial portfolio.

Key Facts

• Founded: 1988
• Headquarters: Tarrytown, NY
• Employees: ~13,500
• Exchange: NASDAQ
• Sector / Industry: Health Care / Biotechnology
• Market Cap: ~$80B (May 2026)
• Initiated quarterly dividend in 2025 (first ever)

ticker: REGN step: 12 generated: 2026-05-12 source: quick-research

Regeneron Pharmaceuticals Inc. (REGN) — Investment Catalysts & Risks

Bull Case Drivers

1. Dupixent continues to scale at unprecedented pace — Q1 2026 Dupixent sales +30.8% globally; $17.8B global FY2025 revenue; 1.4M patients across 8 indications. Approved for atopic dermatitis, asthma, EoE, prurigo nodularis, COPD, CSU, bullous pemphigoid + ongoing indication expansion. As world's most-used innovative branded antibody, Dupixent's growth provides multi-year visibility and structurally elevates Regeneron's profit-share economics regardless of EYLEA dynamics.

2. Eylea HD successfully cannibalizing legacy at convenient interval — Eylea HD captured ~50% of franchise volume by year-end 2025 (FY2025 sales: HD $1.6B +36%, legacy declining 42%). Recent FDA approvals (RVO indication; pre-filled syringe) re-stabilize the franchise. Longer dosing intervals (12-16 weeks) provide a real clinical edge vs. biosimilars stuck on the 8-week legacy schedule and a competitive lane vs. Vabysmo.

3. 2026 = year of pivotal catalysts — Key readouts: fianlimab + Libtayo melanoma (potential $5B+ franchise vs. Keytruda), cemdisiran in generalized myasthenia gravis, C5 program for geographic atrophy (interim Phase 3), odronextamab follicular lymphoma launch, linvoseltamab multiple myeloma. 18 Phase 3 study starts planned + ≥4 FDA approvals expected.

4. Fortress balance sheet enables capital return + opportunistic M&A — $19.4B cash vs. only $2.7B debt = $16.7B net cash. Initiated first-ever quarterly dividend in 2025; $4.5B buyback authorization. Capital allocation now formally returning capital to shareholders, with optionality to fund mid-cap biotech M&A as growth supplement.

Bear Case Risks

1. Eylea biosimilar pressure accelerating faster than HD conversion — Amgen's biosimilar approved despite Regeneron's legal challenge; Opuviz and Yesafili now FDA-approved interchangeable biosimilars (pharmacist substitution legal). Approximately 80% of Eylea franchise revenue still came from the 2mg formulation as of 2025, suggesting HD transition is slower than the bull case requires. If biosimilars erode the legacy 2mg base faster than HD ramps, the franchise net could decline materially through 2027.

2. Vabysmo (Roche) winning share in retinal — Q1 2026 Vabysmo sales $1.2B / +18% YoY globally — Roche's faricimab is rapidly establishing as a long-interval anti-VEGF / Ang-2 inhibitor competitor to EYLEA HD. Retinal physicians increasingly view Vabysmo's dual-mechanism platform as the future, particularly for difficult-to-treat patients. If Vabysmo continues to gain new starts, Eylea HD's path to 70%+ franchise volume becomes harder.

3. FDA rejection / regulatory headwinds on Eylea HD lifecycle — FDA rejected Eylea HD prefilled syringe and rebuffed extended-interval label expansion. Repeated CRLs in 2024/2025 (manufacturing-related) on bispecific programs added regulatory uncertainty. Continued setbacks delay franchise modernization and limit Eylea HD's structural defense vs. biosimilars.

4. Dupixent eventual LOE + Sanofi structure — Long-duration concern (>2030) but increasingly priced in. Composition-of-matter patents protect Dupixent through end of decade in major markets; biosimilar / methods patents extend longer. Any structural change in the Sanofi collaboration (which is highly profitable for Regeneron) would be material — though no near-term catalysts indicate change.

Upcoming Events

• Q2 2026 earnings: Late July 2026 — focus on EYLEA HD conversion progress, Dupixent quarterly growth, biosimilar share commentary
• Fianlimab + Libtayo melanoma Phase 3 readouts: 2026/2027 — most-watched binary event
• C5 program (geographic atrophy) interim data: 2026
• Multiple bispecific FDA reviews: 2026 — odronextamab, linvoseltamab regulatory paths
• Eylea franchise quarterly trends: Monthly Q-on-Q biosimilar share data
• Q3 2026 earnings: Late October 2026

Analyst Sentiment

Sell-side consensus is mixed-to-positive: ~70% Buy / Hold with average 12-month price targets clustering around $700–$850 (vs. current trading around $730). Bulls cite Dupixent dominance + Eylea HD transition + cash deployment optionality. Bears focus on Eylea biosimilar pace + Vabysmo share gains + pipeline execution risk on bispecifics. RBC and others have flagged ongoing Eylea headwinds + Dupixent LOE uncertainty as multiple-compressing factors.

Research Date

Generated: 2026-05-12